生命科学资讯
生物技术与制药领域的最新动态
拜耳为制药业务复苏铺平道路
Bayer sets the stage for a pharma comeback
最有前途的GLP-1类药物
The most valuable up-and-coming GLP-1s
大型药企CEO瞄准未来数年实现大规模增长。
Big Pharma CEOs set sights on massive growth in years to come
特朗普医保计划为何在起步前就步履蹒跚
Why TrumpRx is stumbling before it gets off the ground
投资者青睐更安全、市场成熟度高的生物科技项目，早期融资缺口进一步扩大。
Investors crave safer, market-ready biotech bets, widening the early-stage funding gap
Mirum加倍押注多元化罕见病战略。
Mirum doubles down on diversified rare disease strategy
尽管AI已进入高风险患者护理领域，监管却滞后不前。
AI regulation lags despite entering higher-risk patient care
2026年制药业展望：前路是否更加顺畅？
Pharma’s outlook in 2026: Smoother sailing ahead?
大型制药企业如何应对3000亿美元专利悬崖
How Big Pharma is navigating a $300 billion patent cliff
FDA政治化程度空前加深，长期影响堪忧
Politicization runs deeper than ever at FDA, risking long-term impacts
礼来与BioAge竞逐NLRP3抑制剂，探索“一药多靶点”潜力。
Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential
诺瓦瓦克斯是否已在疫苗领域破解生存密码？
Has Novavax cracked the code for survival in the vaccine arena?
心力衰竭潜在基因疗法，数十年研究终现曙光。
A potential gene therapy for heart failure is an approach decades in the making
生物制药行业去年裁员潮涌，但2026年或迎转机。
Biopharma layoffs surged last year, but 2026 is a chance to turn the page
大型制药公司收购中国生物科技企业以充实GLP-1药物管线
Big Pharma shops Chinese biotechs to stock GLP-1 pipelines
美国药品定价政策成投资者“红灯”，中国市场成新机遇
US drug pricing policies are ‘red lights’ for investors, and China beckons
癌症研发蓬勃发展，2026年值得关注的领域。
Cancer R&D is thriving. Here are the areas to watch in 2026.
礼来与武田制药遭法律策略锁定，通常此类手段仅用于打击黑帮。
Lilly, Takeda targeted by legal strategy usually reserved for the mob
德克萨斯、北卡罗来纳、俄亥俄、宾夕法尼亚——制药制造业投资激增之地
Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged